BERTILIMUMAB

BERTILIMUMAB

Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE August 29, 2017

Immune Pharmaceuticals Receives NASDAQ Letter | Read more 

 

PRESS RELEASE August 28, 2017

Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial Highlights | Read more 

 

PRESS RELEASE August 19, 2017

Immune Pharmaceuticals Receives NASDAQ Letter | Read more 

 

See All News 

Upcoming Events

No upcoming events found

See All Events